These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2824425)

  • 1. In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
    Saito H; Rolston KV; Ho DH; LeBlanc B; Bodey GP
    J Antimicrob Chemother; 1987 Oct; 20(4):497-503. PubMed ID: 2824425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F; Neu HC
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE; Johnston JL; Archer GL
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P; Grenier P; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH; Maher LA; Redding JS
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.
    Debbia E; Pesce A; Schito GC
    Antimicrob Agents Chemother; 1988 Feb; 32(2):279-81. PubMed ID: 2834999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY146032: activity and resistance development in vitro.
    Mouton RP; Mulders SL
    J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
    Huovinen P; Kotilainen P
    Antimicrob Agents Chemother; 1987 Mar; 31(3):455-7. PubMed ID: 3034145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.
    Liebowitz LD; Saunders J; Chalkley LJ; Koornhof HJ
    Antimicrob Agents Chemother; 1988 Jan; 32(1):24-6. PubMed ID: 2831813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of LY146032 against gram-positive bacteria.
    Silva M; Jacobus NV; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):79-85. PubMed ID: 2838217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria.
    Piper KE; Steckelberg JM; Patel R
    J Infect Chemother; 2005 Aug; 11(4):207-9. PubMed ID: 16133715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.